Apolipoprotein e mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Cerda, Alvaro ^a   Genvigir, Fabiana D V ^a   Willrich, Maria A V ^a   Arazi, Simone S ^a   Bernik, Marcia M S ^a   Dorea, Egidio L ^a   Bertolami, Marcelo C ^b   Faludi, Andre A ^b   Hirata, Mario H ^a   Hirata, Rosario D C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

APOE gene expression; apolipoproteina E; atorvastatin; hypercholesterolemia; single nucleotide polymorphism (SNP)

Indexed keywords

APOENZYME; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ATORVASTATIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; APOLIPOPROTEIN E; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; PYRROLE DERIVATIVE;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; AGED; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LEUKOCYTES, MONONUCLEAR; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRROLES; RNA, MESSENGER;

EID: 81055131695     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-206     Document Type: Article

References (43)

1. The key role of apolipoprotein E in atherosclerosis. Greenow K, Pearce NJ, Ramji DP, J Mol Med 2005 83 329 342 10.1007/s00109-004-0631-3 15827760 (Pubitemid 41201798)
2. Molecular biology of apolipoprotein E. Strittmatter WJ, Bova Hill C, Curr Opin Lipidol 2002 13 119 123 10.1097/00041433-200204000-00002 11891413 (Pubitemid 34280762)
3. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Huang Y, Curr Opin Lipidol 2010 21 337 345 10.1097/MOL.0b013e32833af368 20531185
4. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Lancet 2005 366 1267 1278 16214597
5. Clinical implications of pharmacogenomics of statin treatment. Mangravite LM, Thorn CF, Krauss RM, Pharmacogenomics J 2006 6 360 374 10.1038/sj.tpj. 6500384 16550210 (Pubitemid 44811531)
6. APOE gene polymorphisms and response to statin therapy. Zintzaras E, Kitsios GD, Triposkiadis F, Lau J, Raman G, Pharmacogenomics J 2009 9 248 257 10.1038/tpj.2009.25 19529002
7. Genome-wide and candidate genes approach for pharmacogenomics of atorvastatin. Hirata RDC, Hirata MH, Clinical Lipidology 2009 4 419 423 10.2217/clp.09.32
8. IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology. Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune Neto A, Souza AD, Lottenberg AM, Chacra AP, Faludi AA, Loures-Vale AA, et al. Arq Bras Cardiol 2007 88 Suppl 1 2 19 17515982 (Pubitemid 47164157)
9. Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes. Bencharif K, Hoareau L, Murumalla RK, Tarnus E, Tallet F, Clerc RG, Gardes C, Cesari M, Roche R, Lipids Health Dis 2010 9 75 10.1186/1476-511X-9-75 20642861
10. ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages. Von Eckardstein A, Langer C, Engel T, Schaukal I, Cignarella A, Reinhardt J, Lorkowski S, Li Z, Zhou X, Cullen P, Assmann G, FASEB J 2001 15 1555 1561 10.1096/fj.00-0798com 11427487 (Pubitemid 32673385)
11. Apolipoprotein E gene expression in peripheral blood monocyte in children with obesity. Xiang W, Ma YL, Chen C, Fu SM, Yang JF, Zhao SP, Guo DX, Zhao DC, Nie S, Wang FL, Zhonghua Er Ke Za Zhi 2003 41 755 760 14731357
12. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N, J Lipid Res 2009 50 Suppl 178 182 19060252
13. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, Kafatos A, Martins MC, Sans S, Sass C, et al. Atherosclerosis 2000 152 475 488 10.1016/S0021-9150(99)00501-8 10998477
14. Apolipoprotein E polymorphism - a risk factor for metabolic syndrome. Sima A, Iordan A, Stancu C, Clin Chem Lab Med 2007 45 1149 1153 10.1515/CCLM.2007.258 17848120 (Pubitemid 47396270)
15. Genetic and clinical predictors of warfarin dose requirements in African Americans. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA, Clin Pharmacol Ther 2010 87 459 464 10.1038/clpt.2009.223 20072124
16. Comparative study of apolipoprotein-E polymorphism and plasma lipid levels in dyslipidemic and asymptomatic subjects, and their implication in cardio/cerebro-vascular disorders. Ferreira CN, Carvalho MG, Fernandes AP, Lima LM, Loures-Valle AA, Dantas J, Janka Z, Palotas A, Sousa MO, Neurochem Int 2010 56 177 182 10.1016/j.neuint.2009.09.016 19819279
17. Association between apoliprotein E gene polymorphism and hypercholesterolemic phenotype in Maracaibo, Zulia state, Venezuela. Arraiz N, Bermudez V, Prieto C, Sanchez MP, Escalona C, Sanz E, Rondon N, Reyes F, Velasco M, Am J Ther 2010 17 330 336 10.1097/MJT.0b013e3181c1235d 20019593
18. Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto study. Mendes-Lana A, Pena GG, Freitas SN, Lima AA, Nicolato RL, Nascimento-Neto RM, Machado-Coelho GL, Freitas RN, Braz J Med Biol Res 2007 40 49 56 10.1590/S0100-879X2007000100007 17224996 (Pubitemid 46117718)
19. Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study. Gronroos P, Raitakari OT, Kahonen M, Hutri-Kahonen N, Marniemi J, Viikari J, Lehtimaki T, Clin Chem Lab Med 2007 45 592 598 10.1515/CCLM.2007.116 17484618 (Pubitemid 46709739)
20. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS, J Cardiovasc Pharmacol Ther 2006 11 211 221 10.1177/1074248406293732 17056835 (Pubitemid 44536190)
21. Common variants at 30 loci contribute to polygenic dyslipidemia. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, et al. Nat Genet 2009 41 56 65 10.1038/ng.291 19060906
22. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, et al. Nature Genetics 2008 40 161 169 10.1038/ng.76 18193043 (Pubitemid 351171403)
23. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, Ieiri I, J Hum Genet 2006 51 822 826 10.1007/s10038-006-0025-1 16917677 (Pubitemid 44386828)
24. Effect of apolipoprotein E alleles and angiotensin-converting enzyme insertion/deletion polymorphisms on lipid and lipoprotein markers in middle-aged men and in patients with stable angina pectoris or healed myocardial infarction. Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Perret B, Ferrieres J, Am J Cardiol 2003 92 1102 1105 10.1016/j.amjcard.2003.06.008 14583365 (Pubitemid 37329537)
25. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, et al. Pharmacogenomics J 2005 5 352 358 10.1038/sj.tpj.6500328 16103896
26. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, Donnan PT, Pharmacogenet Genomics 2008 18 279 287 10.1097/FPC.0b013e3282f60aad 18334912 (Pubitemid 351367521)
27. The effects of gender and CYP46 and apo E polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients treated with statins. Vega GL, Weiner M, Kolsch H, von Bergmann K, Heun R, Lutjohan D, Nguyen A, Moore C, Curr Alzheimer Res 2004 1 71 77 10.2174/1567205043480546 15975088
28. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. Pena R, Lahoz C, Mostaza JM, Jimenez J, Subirats E, Pinto X, Taboada M, Lopez-Pastor A, J Intern Med 2002 251 518 525 10.1046/j.1365-2796.2002.00991.x 12028507 (Pubitemid 34535524)
29. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH, Clin Chim Acta 2005 362 182 188 10.1016/j.cccn.2005.06.005 16038892 (Pubitemid 41597104)
30. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Nieminen T, Kahonen M, Viiri LE, Gronroos P, Lehtimaki T, Pharmacogenomics 2008 9 1475 1486 10.2217/14622416.9.10.1475 18855536
31. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, Hovingh GK, Kastelein JJ, Circ Cardiovasc Genet 2009 2 173 181 10.1161/CIRCGENETICS.108.818062 20031582
32. Genome-wide association of lipid-lowering response to statins in combined study populations. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, Li X, Wilke RA, Rieder MJ, Williams PT, et al. PLoS One 2010 5 9763 10.1371/journal.pone.0009763 20339536
33. Effect of atorvastatin on ApoE and ApoC-I synthesis and secretion by THP-1 macrophages. Castilho LN, Chamberland A, Boulet L, Davignon J, Cohn JS, Bernier L, J Cardiovasc Pharmacol 2003 42 251 257 10.1097/00005344-200308000- 00015 12883330 (Pubitemid 36899679)
34. Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. Cignarella A, Brennhausen B, von Eckardstein A, Assmann G, Cullen P, Arterioscler Thromb Vasc Biol 1998 18 1322 1329 10.1161/01.ATV.18.8.1322 9714140 (Pubitemid 28376190)
35. HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. Guan JZ, Tamasawa N, Murakami H, Matsui J, Tanabe J, Matsuki K, Yamashita M, Suda T, J Atheroscler Thromb 2008 15 20 25 10.5551/jat.E512 18270459
36. Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Genvigir FD, Soares SA, Hirata MH, Willrich MA, Arazi SS, Rebecchi IM, Oliveira R, Bernik MM, Dorea EL, Bertolami MC, Hirata RD, Clin Chim Acta 2008 389 79 86 10.1016/j.cca.2007.11.029 18164264
37. Dietary recommendations in the prevention and treatment of coronary heart disease: do we have the ideal diet yet? Chahoud G, Aude YW, Mehta JL, Am J Cardiol 2004 94 1260 1267 10.1016/j.amjcard.2004.07.109 15541241 (Pubitemid 39469944)
38. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 499 502 4337382
39. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. Cerda A, Genvigir FD, Arazi SS, Hirata MH, Dorea EL, Bernik MM, Bertolami MC, Faludi AA, Hirata RD, Clin Chim Acta 2010 411 631 637 10.1016/j.cca.2010.01.002 20064494
40. Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease. Salazar LA, Hirata MH, Giannini SD, Forti N, Diament J, Lima TM, Hirata RD, Clin Chim Acta 2000 300 139 149 10.1016/S0009-8981(00)00308-9 10958870 (Pubitemid 30665781)
41. Influence of Polymorphisms and Cholesterol-Lowering Treatment on SCARB1 mRNA Expression. Cerda A, Genvigir FD, Rodrigues AC, Willrich MA, Dorea EL, Bernik MM, Arazi SS, Oliveira R, Hirata MH, Hirata RD, J Atheroscler Thromb 2011 18 640 651 10.5551/jat.6544 21512283
42. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
43. SNPAnalyzer: a web-based integrated workbench for single-nucleotide polymorphism analysis. Yoo J, Seo B, Kim Y, Nucleic Acids Res 2005 33 483 488 10.1093/nar/gki428 15980517 (Pubitemid 44529967)